ClinicalTrials.gg
DrugCombination product

Anifrolumab clinical trials

Also written MEDI-546 and Saphnelo.

studies test it
33
open now
11
in phase 3
13
first study started
2009

How each study uses anifrolumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the anifrolumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Jul 2021 · SAPHNELO · BLA 761123 (FDA, Drugs@FDA)
European Union
14 Feb 2022 · Saphnelo · EMEA/H/C/004975 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Anifrolumab
23
Anifrolumab (blinded)
2
Treatment arm (blinded)
2
Anifrolumab (unblinded, open label)
2

Brand

Saphnelo
5

Development codes

MEDI-546
9

Studies by the year they started

33 studies that test it; most in 2026 (7)

Studies that test anifrolumab, by start year
YearStudies
20091
20122
20131
20154
20161
20171
20181
20214
20222
20233
20245
20251
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
5
Phase 2
12
Phase 3
13
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 8

AstraZeneca (22) · MedImmune LLC (3) · University of North Carolina, Chapel Hill (1) · University of Cambridge (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · National and Kapodistrian University of Athens (1) · University Hospital, Bordeaux (1) · Oklahoma Medical Research Foundation (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 3 in phase 3

Studies that test anifrolumab, phase 3 first.

Studies

Open first, then newest update. How each study uses anifrolumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 33

See all 33 studies that test anifrolumab →

Given beside what is tested · 1 — anifrolumab is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call anifrolumab · ClinicalTrials.gg INT006312

  • MeSH (NLM) C582345anifrolumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 38RL9AE51QANIFROLUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2565265One source FDA
  • Wikidata Q15708296AnifrolumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C166658AnifrolumabOne source FDA
  • DrugBank DB78910One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.